X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs TORRENT PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES TORRENT PHARMA DIVIS LABORATORIES/
TORRENT PHARMA
 
P/E (TTM) x 33.3 37.1 89.8% View Chart
P/BV x 5.4 5.8 93.5% View Chart
Dividend Yield % 0.9 0.9 97.3%  

Financials

 DIVIS LABORATORIES   TORRENT PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
TORRENT PHARMA
Mar-17
DIVIS LABORATORIES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2221,768 69.1%   
Low Rs7841,186 66.1%   
Sales per share (Unadj.) Rs153.1346.1 44.2%  
Earnings per share (Unadj.) Rs39.955.2 72.4%  
Cash flow per share (Unadj.) Rs44.673.3 60.8%  
Dividends per share (Unadj.) Rs10.0014.00 71.4%  
Dividend yield (eoy) %1.00.9 105.2%  
Book value per share (Unadj.) Rs201.8257.1 78.5%  
Shares outstanding (eoy) m265.47169.22 156.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.64.3 153.6%   
Avg P/E ratio x25.126.8 93.8%  
P/CF ratio (eoy) x22.520.1 111.7%  
Price / Book Value ratio x5.05.7 86.5%  
Dividend payout %25.025.4 98.7%   
Avg Mkt Cap Rs m266,266249,887 106.6%   
No. of employees `0009.711.8 82.6%   
Total wages/salary Rs m4,6879,934 47.2%   
Avg. sales/employee Rs Th4,175.04,971.5 84.0%   
Avg. wages/employee Rs Th481.5843.2 57.1%   
Avg. net profit/employee Rs Th1,089.3792.4 137.5%   
INCOME DATA
Net Sales Rs m40,64358,569 69.4%  
Other income Rs m7492,233 33.5%   
Total revenues Rs m41,39260,802 68.1%   
Gross profit Rs m14,46013,773 105.0%  
Depreciation Rs m1,2333,069 40.2%   
Interest Rs m232,056 1.1%   
Profit before tax Rs m13,95310,881 128.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3491,545 216.8%   
Profit after tax Rs m10,6049,336 113.6%  
Gross profit margin %35.623.5 151.3%  
Effective tax rate %24.014.2 169.0%   
Net profit margin %26.115.9 163.7%  
BALANCE SHEET DATA
Current assets Rs m40,10553,841 74.5%   
Current liabilities Rs m6,59531,612 20.9%   
Net working cap to sales %82.538.0 217.2%  
Current ratio x6.11.7 357.1%  
Inventory Days Days11997 122.0%  
Debtors Days Days8184 96.3%  
Net fixed assets Rs m19,99542,079 47.5%   
Share capital Rs m531846 62.7%   
"Free" reserves Rs m53,04342,655 124.4%   
Net worth Rs m53,57443,501 123.2%   
Long term debt Rs m022,408 0.0%   
Total assets Rs m61,585101,250 60.8%  
Interest coverage x618.46.3 9,826.4%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.70.6 114.1%   
Return on assets %17.311.3 153.4%  
Return on equity %19.821.5 92.2%  
Return on capital %26.119.6 132.9%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38420,066 176.3%   
Fx outflow Rs m10,3995,304 196.0%   
Net fx Rs m24,98514,762 169.2%   
CASH FLOW
From Operations Rs m11,49310,127 113.5%  
From Investments Rs m-11,372-7,869 144.5%  
From Financial Activity Rs m-93-1,918 4.9%  
Net Cashflow Rs m28212 13.4%  

Share Holding

Indian Promoters % 52.0 71.5 72.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 7.0 168.1%  
FIIs % 19.0 12.6 150.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 8.8 195.5%  
Shareholders   31,796 26,511 119.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

TORRENT PHARMA at 52 Week High; BSE 500 Index Down 0.3 %

Jun 19, 2018 | Updated on Jun 19, 2018

TORRENT PHARMA share price has hit a 52-week high. It is presently trading at Rs 1,524. BSE 500 Index is down by 0.27% at 14,773. Within the BSE 500, TORRENT PHARMA (up 2.80%) and RELAXO FOOTWEARS (up 5.86%) are among the top gainers, while top losers are MANPASAND BEVERAGES and KRBL LIMITED.

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 19, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS